REG - Destiny Pharma PLC - Grant of share options

Destiny PharmaAnnouncement

08/06/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220608:nRSH0620Oa&default-theme=true

RNS Number : 0620O  Destiny Pharma PLC  08 June 2022

Destiny Pharma plc

("Destiny Pharma" or the "Company")

Grant of share options

Brighton, United Kingdom - 8 June 2022 - Destiny Pharma plc (AIM: DEST, "the
Company") a clinical stage innovative biotechnology company focused on the
development of novel medicines that can prevent life threatening infections,
announces the following options ("Options") over 190,000 ordinary shares of 1
pence in the Company have been granted under the Destiny Pharma plc 2020 Long
Term Incentive Plan (the "Plan") to the following PDMR.

 Name             Position               Total number of Options granted under award  Total Options held

                                                                                      after the grant
 Dr Yuri Martina  Chief Medical Officer  190,000                                      190,000

 

The Options have been granted with an exercise price of £0.46 and will vest
on 8 June 2025. The Options were granted under award agreements that
incorporated the terms of the Plan.

 

For further information, please contact:

Destiny Pharma plc

Neil Clark, CEO

Shaun Claydon, CFO

+44 (0)1273 704 440

pressoffice@destinypharma.com (about%3Ablank)

 

Optimum Strategic Communications  (about%3Ablank)

Mary Clark / Manel Mateus /Vici Rabbetts

+44 (0) 208 078 4357

DestinyPharma@optimumcomms.com (about%3Ablank)

 

finnCap Ltd (Nominated Advisor and Broker)

Geoff Nash / Kate Bannatyne / George Dollemore, Corporate Finance

Alice Lane / Nigel Birks / Harriet Ward, ECM

+44 (0) 207 220 0500

 

MC Services AG

Anne Hennecke / Andreas Burckhardt

+49-211-529252-12

 

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused
on the development of novel medicines that can prevent life-threatening
infections. Its pipeline has novel microbiome-based biotherapeutics and XF
drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the
prevention of C. difficile infection (CDI) recurrence which is the leading
cause of hospital acquired infection in the US and also XF-73 nasal gel, which
has recently completed a positive Phase 2b clinical trial targeting the
prevention of post-surgical staphylococcal hospital infections including MRSA.
It is also co-developing SporCov, a novel, biotherapeutic product for the
prevention of COVID-19 and other viral respiratory infections and has earlier
grant funded XF research projects.

For further information on the company, please visit www.destinypharma.com
(http://www.destinypharma.com)

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them

 1.                                Details of the person discharging managerial responsibilities / person closely
                                   associated
 a)                                Name                                                         Yuri Martina
 2.                                Reason for the Notification
 a)                                Position/status                                              Chief Medical Officer
 b)                                Initial notification/Amendment                               Initial notification
 3.                                Details of the issuer, emission allowance market participant, auction
                                   platform, auctioneer or auction monitor
 a)                                Name                                                         Destiny Pharma plc
 b)                                LEI                                                          213800O9WH9Z38EHAC95
 4.                                Details of the transaction(s): section to be repeated for (i) each type of
                                   instrument; (ii) each type of transaction; (iii) each date; and (iv) each
                                   place where transactions have been conducted
 a)                                Description of the Financial instrument, type of instrument  Grant of award of options over ordinary shares of 1 pence each ("Ordinary
                                                                                                Shares") under the 2020 Destiny Pharma plc Long Term Incentive Plan.

                                   Identification code                                          DEST      GB00BDHSP575
 b)                                Nature of the transaction                                    Grant of award of options over Ordinary Shares under the 2020 Destiny Pharma
                                                                                                plc Long Term Incentive Plan.
 c)                                Price(s) and volume(s)                                       £0.46 pence exercise price per Ordinary Share

                                                                                                190,000 Ordinary Shares
 d)                                Aggregated information:

                                   Aggregated volume                                            See 4c) above

                                   Price
 e)                                Date of the transaction                                      8 June 2022
 f)                                Place of the transaction                                     London Stock Exchange, AIM Market

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFRMFTMTIMBJT